Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy

ConclusionsFinerenone administered as a monotherapy is disease modifying for both skeletal muscle and heart in a preclinical DMD model. These findings support further evaluation of finerenone in DMD clinical trials.

Source: ESC Heart Failure - September 17, 2020 Category: Cardiology Authors: Jeovanna Lowe, Peter Kolkhof, Michael J. Haupt, Kyra K. Peczkowski, Neha Rastogi, J. Spencer Hauck, Feni K. Kadakia, Jonathan G. Zins, Pierce C. Ciccone, Suzanne Smart, Peter Sandner, Subha V. Raman, Paul M.L. Janssen, Jill A. Rafael ‐Fortn Tags: Original Research Article Source Type: research